

Maintaining the blind for clinical trials in Pharmacy

**IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO ENSURE THAT
THE CORRECT VERSION IS BEING USED**

All staff should regularly check the R&D Unit's website and/or Q-Pulse for information relating to the implementation of new or revised versions. Staff must ensure that they are adequately trained in the new procedure and must make sure that all copies of superseded versions are promptly withdrawn from use unless notified otherwise by the SOP Controller.

The definitive versions of all R&D Unit SOPs appear online. If you are reading this in printed form check that the version number and date below is the most recent one as shown on the R&D Unit website: www.research.yorkhospitals.nhs.uk/sops-and-guidance-/ and/or Q-Pulse

SOP Reference:	Pharm/S89
Version Number:	3.0
Author:	Cheryl Donne
Implementation date of current version:	11 th July 2023

Approved by:	Name/Position:	Poppy Cottrell-Howe – Pharmacy Clinical Trials Manager
	Date:	25 th May 2023
	Name/Position:	Sarah Sheath, SOP Controller
	Date:	13 th June 2023

This SOP will normally be reviewed every 3 years unless changes to the legislation require otherwise

Version History Log

This area should detail the version history for this document. It should detail the key elements of the changes to the versions.

	Date Implemented	Reviewers	Details of significant changes
1.0	20 th August 2015		
2.0	8 th April 2019		Change of author. Change to link for R&D website, minor changes and updated.
3.0	11 th July 2023	Dominic Burns Poppy Cottrell-Howe	Minor changes

UNCONTROLLED DOCUMENT WHEN PRINTED

Contents

	<u>Page No</u>
1. Introduction, Background and Purpose	1
2. Who Should Use This SOP	1
3. When this SOP Should be Used	1
4. Procedure(s)	2
5. Related SOPs and Documents	4

UNCONTROLLED DOCUMENT WHEN PRINTED

1. Introduction, Background and Purpose

The MHRA Good Clinical Practice Guide states that 'Blinding is the process that keeps one or more parties involved in a trial unaware of what treatment arm subjects have been randomised to. It is vital that the blind is maintained throughout the trial to ensure that no bias is introduced when making safety and efficacy statements'.

In maintaining the blind for a clinical trial the following are important items to consider;

- Code break envelopes
- Randomisation lists
- Patient Logs that indicate treatment arms
- Drug administration records

Pharmacy may have a role in handling these items and therefore have an important role in maintaining the blinding arrangements in a study. The study design and therefore the specific blinding arrangements for a trial should be clear when constructing the pharmacy trial SOP/trial instructions.

The purpose of this SOP is to describe the procedures or actions that should be considered/undertaken by Pharmacy to ensure that blinding for a trial is maintained and prevent inadvertent un-blinding of the trial. All trial specific information should be recorded in the trial set up forms and be communicated in the Pharmacy trial SOP's/trial instructions.

2. Who Should Use This SOP

This SOP should be used by all members of the Pharmacy clinical trials team. There may be circumstances where this SOP is also applicable to the Principal Investigator and other members of the local research team.

3. When this SOP Should be Used

This SOP should be used whenever it has been identified that Pharmacy will have a role in one or all of the following activities;

- Sourcing IMP for a blinded trial.
- Dispensing for participants from a randomisation document that identifies patient treatment allocation.
- Handling of code break envelopes. or a role in other methods of un-blinding the trial
- The blinding of IMP or other products/devices for studies.
- Working as an un-blinded team member in a trial.

This SOP should be used when preparing Pharmacy SOPs/trial instructions to ensure that blinding for a relevant trial is maintained.

4. Procedure(s)

The arrangements for maintaining the blind for a clinical trial should be considered in detail and those arrangements carefully planned, documented and communicated to ensure inadvertent un-blinding is avoided.

Pharmacy SOPs/trial instructions should be written detailing what actions need to be taken to maintain the blind and who will be responsible for these actions. These are likely to be very specific to each blinded trial.

In Each clinical trial that involves any sort of blinding requirements. The following things should be considered

- Manufacture of the Investigational Medicinal product
- Handling of code break envelopes and other methods used for un-blinding
- Handling of randomisation documents and other methods used for randomisation
- Aseptic preparation of IMP
- Communication with the Research Team
- Communication with the Sponsor
- Invoicing and stock management for blinded trials
- Destruction of IMP
- Training

The Pharmacy trial instructions should be created, reviewed and approved in line with those procedures detailed in Pharm/S50 – Preparation, review and approval of Pharmacy study specific trial instructions.

The following sections contain guidance on what should be considered when writing the Pharmacy trial instructions to maintain the blind for a study. This guidance is not intended to be universally applicable and there may be study specific arrangements in this respect that are not covered here. The Sponsor should be consulted as appropriate.

Manufacture of the Investigational Medicinal product

Correct manufacturing and assembly processes are vital in ensuring that the blind is maintained. If Pharmacy is involved in sourcing IMP for use in a blinded trial, this should be considered as part of the Technical agreement put in place to cover IMP manufacture for the clinical trial.

Handling of code break envelopes and other methods of un-blinding

Consideration should be given as to;

- How code break envelopes are reconciled at the end of the trial to ensure that they have not been tampered with.
- The process of Un-blinding a subject in the trial. This process should not un-blind the whole trial, and where possible the trial team should not be informed.
- How code break envelopes are to be controlled in a manner so that, once opened, they are not available to any members of the blinded Research Team.

Handling documents that show treatment /randomisations

Consideration should be given as to;

- How these will be stored and controlled so that they are kept under the control of those personnel un-blinded to treatment allocation only
- When IRT (Interactive Response Technologies) systems for randomisation are being used, care needs to be taken that no information is forwarded to

unblinded members of the research team or sponsors. Clear instructions on trial specific details will be in the Pharmacy Trial SOP and this should be referred to when required.

Aseptic preparation of IMP

The following should be considered here:

- Training to ensure that Pharmacy staff in Aseptics units do not inadvertently un-blind the study if contacted by the Research team.
- Procedures and worksheets designed to ensure labelling of the prepared product does not inadvertently un-blind the clinical trial.
- The procedure for blinding any prepared infusions should be documented and where possible tamper proof tape should be used to ensure that the blinding has been maintained during the process of IMP administration.
- How preparation worksheets should be controlled in such a manner that they are only available to be viewed by un-blinded personnel.

Where un-blinded members of the research team have been delegated to prepare study drug outside Pharmacy, the trial treatment should be prepared in a quiet area, out of site from the blinded research team and the patient (if they are blinded also). A member of the un-blinded research team (who is listed on the delegation log as being responsible for this activity) should prepare the infusion.

Communication with the Research Team

The Following should be considered:

- Which members of the Research team are un-blinded and blinded. Some studies may have separate blinded and un-blinded members of the Research team.
- How Pharmacy is made aware of any changes in which members of the Research Teams are blinded and un-blinded (blinded and un-blinded team members should not switch roles during the study).
- How to ensure that patient treatment is only discussed with those un-blinded to patient treatment allocation.

In studies that involve Pharmacy dealing with a blinded and un-blinded research team, the following should also be considered:

- Prescribing study treatment (if applicable)

If this is being done by an un-blinded Principal Investigator, consideration should be given as to the handling of the prescription in such a manner as to not indicate treatment allocation to blinded members of the research team

- Dispensing study treatment

In trials, where Pharmacy are un-blinded and giving out to an un-blinded member of the research team, the medication dispensed should be given to a member of the un-blinded research team in an opaque bag to ensure that the contents cannot be seen by members of the blinded research team, or the patient. A photocopy of the prescription should not be given to the un-blinded research team, unless it is clear how this information will be handled in a way that doesn't un-blind the study. If this is not suitable then arrangements should be made and document the procedure in the pharmacy study instructions/SOP.

- Disposal and/or return of prepared products

Care should be taken to ensure that the study medication is disposed of by un-blinded staff in line with standard hospital procedures, and in a concealed manner. Signature of staff to prompt and confirm this activity is often useful to support compliance.

Consideration should be given as to how items will be returned to pharmacy to prevent inadvertent un-blinding of the trial. The process will be documented within the pharmacy study instructions/SOP. In this circumstance, an opaque bag could be used to prevent the medication being viewed by blinded members of the research team.

Communication with the Sponsor

Consideration should be made for those studies in which there is an un-blinded and blinded Clinical Research Associate (CRA). In these circumstances the trial instructions should document:

- How to ensure Pharmacy staff are aware which CRA's are blinded and un-blinded.
- That un-blinded information e.g. patient treatment should not be shared with the blinded CRA.
- What should be made available to whom during monitoring visits, and other contact, with Pharmacy (e.g. files may be marked as containing un-blinded information to prevent inadvertent un-blinding).

Invoicing and stock management for Blinded trials

Consideration should be given to those trials involving commercial hospital stock and the use of computer dispensing systems e.g. JAC where IMP will need to be booked out to a Consultant during the process of preparation. The trial instructions should consider a process whereby this does not un-blind the study at a later date e.g. when Finance reports are run detailing what was booked out on the dispensing system.

Invoicing the Sponsor for the drug costs associated with blinded trials should be carefully considered in these trials and potentially conducted at the end of the study. This will ensure that the Sponsor and the Trial Management team are not un-blinded to the treatment each patient has received.

Training

All staff working on a study will need to read and acknowledge the Pharmacy Trial instructions/SOP. Training will be recorded on a training log kept within the pharmacy site file. All specific information will be contained in the specific trial documentation.

5. Related SOPs and Documents

Pharm/S50 Preparation, review, and approval of Pharmacy trial instructions